HAL (France)open access
Efficacy and Safety of Rituximab Therapy to Sustain Remission in Young Children With Childhood Nephrotic Syndrome
Children, Anti-CD20 children FSGS minimal change disease nephrotic syndrome rituximab, 0, 2, FSGS, 1, Minimal change disease, Nephrotic syndrome
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 262012
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.